90 Wren C, Campbell RW The response of paediatric arrhythmias to intravenous and oral flecainide Br Heart J 1987;57(2):171–175 91 Berns E, Rinkenberger RL, Jeang MK, et al Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation Am J Cardiol 1987;59(15):1337–1341 92 Anderson JL, Stewart JR, Perry BA, et al Oral flecainide acetate for the treatment of ventricular arrhythmias N Engl J Med 1981;305(9):473– 477 93 Perry JC, Garson A Jr Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing Am Heart J 1992;124(6):1614–1621 94 Perry JC, McQuinn RL, Smith RT Jr, et al Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics J Am Coll Cardiol 1989;14(1):185–191 [discussion 192–193] 95 Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation Europace 2011;13(2):161–173 96 McQuinn RL, Quarfoth GJ, Johnson JD, et al Biotransformation and elimination of 14c- flecainide acetate in humans Drug Metab Dispos 1984;12(4):414–420 97 Conard GJ, Ober RE Metabolism of flecainide Am J Cardiol 1984;53(5):41B–51B 98 Conard GJ, Carlson GL, Frost JW, et al Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans Clin Ther 1984;6(5):643–652 99 Mikus G, Gross AS, Beckmann J, et al The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide Clin Pharmacol Ther 1989;45(5):562–567 100 Lim KS, Cho JY, Jang IJ, et al Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects Br J Clin Pharmacol 2008;66(5):660–666 101 Doki K, Homma M, Kuga K, et al Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia Eur J Clin Pharmacol 2006;62(11):919–926 102 Funck-Brentano C, Becquemont L, Kroemer HK, et al Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone Clin Pharmacol Ther 1994;55(3):256–269 103 Tenneze L, Tarral E, Ducloux N, FunckBrentano C Pharmacokinetics and electrocardiographic effects of a new controlledrelease form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism Clin Pharmacol Ther 2002;72(2):112–122 104 Swen JJ, Nijenhuis M, de Boer A, et al Pharmacogenetics: from bench to byte–an update of guidelines Clin Pharmacol Ther 2011;89(5):662–673 105 Brown JT, Abdel-Rahman SM, van Haandel L, et al Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD Clin Pharmacol Ther 2016;99(6):642–650 106 Van Driest SL, Webber SA Pharmacogenomics: personalizing pediatric heart transplantation Circulation 2015;131(5):503–512 107 Huang W, Lin YS, McConn DJ 2nd, et al Evidence of significant contribution from CYP3A5 to hepatic drug metabolism Drug Metab Dispos 2004;32(12):1434–1445 108 Gijsen V, Mital S, van Schaik RH, et al Age and CYP3A5 genotype affect tacrolimus dosing ... Clin Pharmacol Ther 2016;99(6):642–650 106 Van Driest SL, Webber SA Pharmacogenomics: personalizing pediatric heart transplantation Circulation 2015;131(5):503–512 107 Huang W, Lin YS, McConn DJ 2nd, et al